An October 2026 report highlights non-prescribed testosterone use. Learn how clinicians distinguish reported benefits from diagnosis and fertility concerns.
On October 20, 2026, the New York Post published a report about men using non-prescribed testosterone injections to pursue muscle, energy and libido changes. The article described the practice as “testmaxxing” and included clinicians’ warnings about suppression of natural testosterone and sperm production.
This article is for informational purposes only. It is not medical advice or a substitute for assessment by a qualified clinician.
The Post’s interviews centered on desired changes in appearance and performance. Its subjects described seeking greater strength or energy rather than starting treatment after a documented clinical assessment of testosterone deficiency.
Aiden said he began pursuing physique changes at age 30. According to the Post, he had not consulted a physician for testosterone testing before starting injections and completed three hormone cycles over two years. He reported improved energy and focus, along with greater motivation. He also described better strength and recovery as well as shoulder acne.
Henry, described as being in his 30s, said a routine blood test had not indicated testosterone deficiency. He nevertheless obtained testosterone from an unofficial supplier. After three months, he reported changes in strength and mood and said he had not noticed side effects.
The distinction between these starting points matters. Aiden described proceeding without a physician’s testosterone assessment. Henry described proceeding despite a test that had not indicated deficiency. Neither account provides the combination of clinical findings and repeated low measurements required by the European Association of Urology guideline for diagnosing late-onset hypogonadism.
For readers drawn to the reported benefits, the central question is not simply whether either man felt different. It is whether a clinical need for testosterone had been established. That question separates a performance goal from the diagnostic process used to assess possible hormone deficiency.
Dr. Moss, quoted in the Post, warned that testosterone can suppress the body’s natural testosterone production and inhibit sperm production. Those are the specific physiological concerns highlighted by the report’s clinical commentary.
This makes fertility a relevant part of the discussion even when someone’s original goal is unrelated to having children. The intended outcome may be more strength or a change in libido. The clinician’s warning concerns a different outcome: reduced sperm production.
The report also illustrates why sexual interest and fertility should not be treated as interchangeable measures. A person’s account of libido does not answer the separate question raised by Dr. Moss about sperm production. Feeling a desired effect is not a substitute for assessing the physiological effects that matter to clinical care.
Dr. Alukal, also quoted in the Post, advised against testosterone or testosterone boosters for men whose hormone levels are normal. He cited potentially serious health risks. His warning was not an endorsement of non-prescribed use when the goal is cosmetic or performance-related.
The relevant contrast is therefore not between men who welcome the reported effects and men who do not. It is between a treatment decision grounded in clinical assessment and hormone use undertaken without that foundation. The reported experiences should be read alongside the clinicians’ warnings rather than as an answer to them.
The European Association of Urology guideline calls for compatible signs and symptoms together with consistently low morning testosterone to diagnose late-onset hypogonadism. Measurements should be taken on at least two occasions using a reliable assay under fasting conditions.
That approach brings symptoms and laboratory evidence into the same assessment. Neither a desired physique change nor a single account of improved gym performance supplies that combination. A reported response after starting testosterone does not establish that the person had a deficiency beforehand.
The guideline also gives repeated measurements a specific role. Consistently low results are part of the diagnostic requirement rather than an optional addition to a symptom-based conclusion. Testostra’s explanation of why clinicians seek confirmation across separate blood tests provides further context for that distinction.
Symptoms still deserve attention. Dr. Alukal identified a lack of morning erections or a significant change in libido as reasons for investigation. The important word is investigation: these changes warrant assessment rather than an automatic conclusion that testosterone is needed.
For someone trying to interpret a change in energy or sexual interest, the useful starting question is what the symptoms mean in clinical context. It is not whether another man reported feeling better after an injection. Our overview of how symptoms and laboratory findings fit together addresses that broader assessment.
Testing people with symptoms is also different from screening an entire population. In its September 24, 2026 statement, the Endocrine Society said evidence was insufficient to support population-level screening for hypogonadism in asymptomatic men.
These positions are not competing messages. The European guideline describes the evidence needed for a diagnosis within its scope. The Endocrine Society statement addresses testing people who have no symptoms. Neither supports turning general interest in testosterone into a presumption that every man needs testing or treatment.
The Post article is a news report rather than a controlled clinical study. Its two central interviewees used pseudonyms, and their experiences were individual self-reports. The report did not independently verify their claimed benefits or the contents of Henry’s product.
There was no comparison group or long-term follow-up. The interviews therefore do not establish that testosterone caused the reported improvements or show what outcomes are typical. Henry’s statement that he had not noticed side effects describes his experience at that point rather than a clinical safety finding.
The report also did not quantify how many young men were using non-prescribed testosterone. It cited a 30% year-over-year increase in U.S. Google searches for “testosterone” without giving search volumes, exact comparison dates or methodology. Search interest is not a measurement of how many people obtained or injected the hormone.
Separate reporting by AAMC adds a clinician’s perspective on the concern. Jason Nagata, a UCSF associate professor quoted by AAMC, said young men were increasingly turning to testosterone and other muscle-building substances. He said young men he had encountered using testosterone for muscle building typically obtained it without a prescription. That observation provides clinical context rather than a population-level estimate.
The European guideline’s scope also needs to remain clear. Its diagnostic recommendations concern late-onset hypogonadism. They should not be presented as a complete treatment pathway for every younger man described in reporting about performance-related hormone use.
Taken together, these sources support concern and a clear diagnostic distinction. They do not provide a controlled assessment of “testmaxxing” or a reliable measure of its prevalence. The honest interpretation is narrower than either a claim of widespread benefit or a claim that every user will experience the same harm.
The October report does not provide evidence that should immediately change medical practice. It adds timely examples of non-prescribed use and brings existing clinical concerns into public view. It does not introduce a new diagnostic standard or establish a new treatment benefit.
For possible low testosterone, the relevant standard remains an assessment that connects compatible symptoms with appropriate laboratory evidence. Reported improvements in energy or performance do not replace that process. Men with normal hormone levels should not interpret the interviews as evidence that testosterone or boosters are appropriate for them, given Dr. Alukal’s warning.
The practical distinction can be expressed through a few clinical questions:
These are questions for qualified care rather than a self-treatment checklist. For someone concerned about a notable libido change or absent morning erections, the Post’s clinical commentary supports investigation. It does not support choosing an injection regimen from an online account.
For someone already using non-prescribed testosterone, personal decisions about further use belong in a clinical conversation. That discussion can include the reported exposure, current symptoms and fertility concerns. This article does not provide a dosing plan or instructions for changing hormone use.
The bottom line: the report strengthens the case for careful assessment, not broader self-prescribing. Its most useful message is that a desired change in strength or energy is different from evidence of testosterone deficiency. Clinical decisions should remain grounded in symptoms, appropriate testing and a discussion of risks.
More specific questions about energy and libido are a useful outcome of understanding testosterone evidence, which Testostra explains in plain language. For men uncertain about possible low testosterone symptoms and their causes, its coverage of testing and emerging research adds context while maintaining a clear boundary between education and personal medical advice.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra